Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Placebo of aprepitant
DRUG
2 trials
Sponsors
Sun Yat-sen University
, University Hospital, Brest
Conditions
Aquagenic Pruritus
Myeloproliferative Disorder
Non-small Cell Lung Cancer
Phase 2
Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment
Completed
NCT02646020
Sun Yat-sen University
Non-small Cell Lung Cancer
Start: 2015-12-31
End: 2020-12-01
Updated: 2021-05-18
Phase 3
Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
Completed
NCT03808805
University Hospital, Brest
Aquagenic Pruritus, Myeloproliferative Disorder
Start: 2019-04-16
End: 2024-08-22
Updated: 2025-12-03
Related Papers
Comparison of aprepitant versus desloratadine for EGFR‐TKI‐induced pruritus: A randomized phase 2 clinical trial
Cancer
2022-10-05
11 citations
Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP
Trials
2021-12-19
9 citations